We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. OK, I agree | Cookies Policy

You are here

Magazine

4

New scientific publication on Mucoprotection and diarrheal processes.

Szajewska H, Kołodziej M, Łukasik J. Drug development and acute gastrointestinal infections. Expert Opin Investig Drugs. 2017 Dec 26:1-6

Clarifying the role of intestinal mucus in reducing inflammation and infection has led to the development of ‘mucosal protectors’. These agents form a bioprotective film in the gastrointestinal tract and potentially may prevent microorganisms from crossing the mucus barrier. To date, the most widely studied substances include xyloglucan (Xilaplus®) and gelatin tannate (Tasectan®, Gelenterum®). 2 new clinical studies are about to start to increase the body of evidence of those substances. Szajewska H, Kołodziej M, Łukasik J. Drug development and acute gastrointestinal infections. Expert Opin Investig Drugs. 2017 Dec 26:1-6

Read more

Aprotecol® drops Launched In Italy

We are pleased to announce the launch of APROTECOL® drops, our product for reducing the symptoms of infant colic, in Italy. The product is distributed by Pierre Fabre. Aprotecol® drops is a Class IIa CE marked medical device intended for the treatment of meteorism, aerophagy and flatulent colic in infants and children. Aprotecol® has been available as drops for oral administration in pharmacies and presented to pediatricians all across Italy since the beginning of January. Aprotecol® drops is a class IIa medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (CE 0476, Noventure SL)

Read more

Congresses: Noventure presents its new IBS product Gelsectan® at the 25th UEG week in Barcelona, Spain.

Noventure has participated in the recent 25th UEG week, one of the world’s most important meetings in the field of gastroenterology, which attracts clinicians and basic scientists from all over the world. For the first time the “Gelsectan®” brand was presented at the Noventure stand, now that the medical device is available in its first market, Spain. Gelsectan® belongs to a new class of products defined as “mucosal protectors”, which help restore the normal function of the epithelial barrier in the gut. It is intended to relieve and prevent IBS symptoms such as chronic or relapsing diarrhoea, pain and bloating.

Read more

Let's meet in..

2018, May 26

EAACI 2018

Read more

2018, May 28

PharmaVenue May 2018

Read more

2018, Jun 11

EuroPLX 67

Read more

2018, Aug 29

FNM 2018

FNM-2018-Amsterdam
Read more

2018, Oct 24

UEG Week 2018

Read more